Podcasts about Anurag Agrawal

In this conversation, Host Dr. Riley Kirk and Dr. Anurag Agrawal discuss the intricate relationship between monarch butterflies and milkweed, exploring themes of coevolution, chemical ecology, and the ecological arms race. He explains how monarchs have adapted to survive the toxic compounds in milkweed, the challenges they face due to habitat destruction and pesticides, and the importance of conservation efforts. The discussion highlights the fascinating dynamics of species interactions and the need for community involvement in preserving biodiversity. Chapters 00:00 Introduction to Monarchs and Milkweed 06:32 The Co-evolutionary Dance 11:32 Monarchs vs. Milkweed: The Arms Race 20:14 The Role of Cardiac Glycosides 30:01 Sequestration and Survival Strategies 31:37 The Journey of Monarch Butterflies 37:30 Understanding Monarch Population Decline 46:49 Human Impact on Monarchs and Conservation Efforts 54:01 Exploring Other Fascinating Insects Follow Dr.Agrawal's research: https://ecologyandevolution.cornell.edu/anurag-agrawal https://agrawal.eeb.cornell.edu/ Read or listen to Monarchs and Milkweed https://www.amazon.com/Monarchs-Milkweed-Migrating-Remarkable-Coevolution/dp/0691166358 Preorder my book Reefer Wellness! ⁠⁠https://www.amazon.com/Reefer-Wellness-Understanding-Cannabis-Medicine/dp/0593847156⁠⁠ ✨ Want Exclusive Content? Join the Bioactive Patreon community for as little as $1/month to ask guests your burning questions, access exclusive content, and connect with Dr. Kirk one-on-one.⁠⁠ www.Patreon.com/Cannabichem⁠⁠

In this episode of the Business of Tech Lounge, host Dave Sobel welcomes Anurag Agrawal, Chief Global Analyst and CEO of TechIsle, to discuss key trends that SMBs and mid-market companies should watch for in 2025. They explore the rise of agentic AI, the impact of AI-powered PCs, and how SMBs can effectively tackle their top business goals and IT challenges. Anurag shares his insights based on nearly 40 years of industry experience, providing valuable predictions and strategies for technology priorities in the upcoming yea All our Sponsors: https://businessof.tech/sponsors/ Do you want the show on your podcast app or the written versions of the stories? Subscribe to the Business of Tech: https://www.businessof.tech/subscribe/Looking for a link from the stories? The entire script of the show, with links to articles, are posted in each story on https://www.businessof.tech/ Support the show on Patreon: https://patreon.com/mspradio/ Want to be a guest on Business of Tech: Daily 10-Minute IT Services Insights? Send Dave Sobel a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/businessoftech Want our stuff? Cool Merch? Wear “Why Do We Care?” - Visit https://mspradio.myspreadshop.com Follow us on:LinkedIn: https://www.linkedin.com/company/28908079/YouTube: https://youtube.com/mspradio/Facebook: https://www.facebook.com/mspradionews/Instagram: https://www.instagram.com/mspradio/TikTok: https://www.tiktok.com/@businessoftechBluesky: https://bsky.app/profile/businessof.tech

The annual monarch butterfly migration south starts this month, so I thought it would be a good time to revisit my conversation with ecologist and evolutionary scientist Dr. Anurag Agrawal, an expert on monarch butterflies and milkweed — the only type of plant that monarchs lay their eggs on. Podcast Links for Show notes Download my free eBook 5 Steps to Your Best Garden Ever - the 5 most important steps anyone can do to have a thriving garden or landscape. It's what I still do today, without exception to get incredible results, even in the most challenging conditions. Subscribe to the joegardener® email list to receive weekly updates about new podcast episodes, seasonal gardening tips, and online gardening course announcements. Check out The joegardener® Online Gardening Academy for our growing library of organic gardening courses. Follow joegardener® on Instagram, Facebook, Pinterest, and Twitter, and subscribe to The joegardenerTV YouTube channel.

Dr. Anurag Agrawal of Cornell University describes the many ways that plants defend themselves against locally indigenous insects, and how the insects defuse and even become dependent on the plants' defense mechanisms

Dave Sobel welcomes Anurag Agarwal from TechIsle to discuss research data on customer expectations, cybersecurity, and AI trends. The conversation delves into the increasing budget allocations for IT security among SMBs, highlighting the importance of consulting services in guiding SMBs towards choosing the right security technologies and frameworks. Anurag emphasizes the shift towards cybersecurity as a business risk, prompting SMBs to focus on cyber resiliency rather than just cybersecurity. The discussion then transitions to the evolving landscape of AI adoption, with a focus on large language models (LLMs) and their impact on businesses. Anurag and Dave explore the significance of AI consulting in preparing organizations for AI implementation, emphasizing the need for expertise in selecting the right language models for specific business problems. The conversation underscores the importance of aligning with a single hyperscaler for AI solutions and the emerging trend towards small language models (SLMs) for accelerated AI adoption. Anurag highlights the growing trend of AI assessment as a key focus for both partners and end customers, surpassing cloud cost optimization and security assessments. Supported by: https://salesbuildr.com/   All our Sponsors: https://businessof.tech/sponsors/ Do you want the show on your podcast app or the written versions of the stories? Subscribe to the Business of Tech: https://www.businessof.tech/subscribe/Looking for a link from the stories? The entire script of the show, with links to articles, are posted in each story on https://www.businessof.tech/ Support the show on Patreon: https://patreon.com/mspradio/ Want our stuff? Cool Merch? Wear “Why Do We Care?” - Visit https://mspradio.myspreadshop.com Follow us on:LinkedIn: https://www.linkedin.com/company/28908079/YouTube: https://youtube.com/mspradio/Facebook: https://www.facebook.com/mspradionews/Instagram: https://www.instagram.com/mspradio/TikTok: https://www.tiktok.com/@businessoftechBluesky: https://bsky.app/profile/businessoftech.bsky.social

Ready to unlock the secrets of the SMB and mid-market channel? Join us on Partnerships Unraveled as we navigate this evolving landscape with Anurag Agrawal from TechAisle. Discover how industry giants like Cisco and Microsoft are directing their efforts toward these segments.Anurag shares his valuable insights on SMBs' unique behaviors and challenges, their keen interest in AI and cloud solutions, and the essential shift toward customer-centric strategies for engaging smaller, loyalty-driven partners.We also tackle the complexities that IT vendors face when it comes to channel marketing and partner incentives. Learn the vital importance of marketing both to and through partners, and the transition from traditional monolithic systems to adaptable modular stacks. Anurag delves into the diminishing role of Market Development Funds (MDF) and the rise of Solution Development Funds (SDF) and outcome-based financing, which are proving to be more impactful. Tune in to understand how AI-powered PCs and workshops can drive SMB success, and why extended battery life and business application compatibility are crucial. This episode is packed with actionable strategies for vendors aiming to thrive in this competitive market.Connect with Anurag: https://www.linkedin.com/in/anuragagrawal1/_________________________Learn more about Channext

Grab your favorite botanical drink to enjoy during this happy hour with author and professor Dr. Anurag Agrawal. Let your heart flutter as we discuss the complex interactions between monarch butterflies and their favorite food, milkweeds! Check out Dr. Anurag Agrawal's book Monarchs and Milkweeds! Check out these cool folk Dr. Anurag Agrawal Song into by coldbrew Cover art by Gabbie Moffat

As Covid-19 cases rise across states, Public Health Foundation of India's Dr K Srinath Reddy and Dr Anurag Agrawal at Ashoka University answer queries on what we should be concerned about.

My guests in this episode are Dr. Carrie Olson-Manning and Sydney Kreutzmann. Dr. Olson-Manning is an Assistant Professor at Augustana University, has a Ph.D. in Evolutionary Genetics from Duke University, and leads the Olson-Manning Lab which focuses on understanding how biochemical pathways evolve.Sydney Kreutzmann is a Research Technician in Dr. Olson-Manning's lab, working on a number of research and outreach efforts.In today's episode, we focus on milkweed, and in particular, the Common Milkweed, Asclepias syriaca, of the eastern United States, and the Showy Milkweed, Asclepias speciosa, of the arid west. Dr. Olson-Manning's lab is studying how these two species hybridize in the transition zone in the Great Plains, where humid eastern climates give way to arid western climates. They discuss some of their initial findings, but as is often the case, each discovery opens up many new questions.But to do milkweeds justice, we also get deep into many broader aspects of milkweed, discussing their diversity, speciation, and ranges. No discussion of milkweed is complete without coverage of milkweed toxicity, and the unique animals that rely on it despite this toxicity. And of course, this means some Monarch butterfly talk. But did you know that there are at least 10 other species that rely on milkweed as part of their lifecycle?And one other amazing fact - milkweed produce dopamine. Yes, the same dopamine that you and I rely on. You'll have to listen to hear how it is put to use.Be sure to check out Dr. Olson-Manning's lab, milkweedflower.org for more details on the common and showy milkweed hybridization research, and their instagram. You can also follow the Olson-Manning lab on iNaturalist, and join their iNaturalist project that tracks observations of the Showy and Common milkweeds and their hybrids.Full Show Notes HereLinks and ReferencesPast Episodes MentionedPollinator Posse and the Western MonarchCharley Eiseman and LeafminersBooks and ResourcesMonarchs and Milkweed by Anurag Agrawal, also available as an audiobook!Monarch Joint Venture - a resource mentioned by Dr. Olson-ManningWhat Milkweed To Plant - PDF showing which species to plan by region of the USAPeople, Organizations, and Other ThingsDr. Steven Matzner - collaborator iNaturalist - anyone can use this wonderful resource to learn about the plants, animals, fungi, and other things living in their area.Mead's Milkweed - a milkweed species that is threatenedTropical Milkweed - is NOT recommended by Xerces Society. We discuss this briefly in the episode.Note: links to books are affiliate links

Why are monarchs and milkweed important, and what is it like to write a popular science book? Dr. Anurag Agrawal, a Professor of environmental studies at Cornell University and author of Monarchs and Milkweed, discusses insect-plant interactions, comparative biology, and tips for students in the biological sciences. Follow Anurag on Twitter @anuragasclepias! Learn more about the students producing this podcast and their science communication efforts by following us on Twitter @SciCommUCR and visiting our website.

Edge is the place where data from people, places, things, and their locations gets created. Hear from Anurag Agrawal, Founder and Head Analyst at Techaisle on how SMBs can gain time to value more quickly if data is computed and analyzed at the Edge. This faster time to value empowers distributed work, enables improved customer intimacy, and drives innovation.

Ben chats with Anurag Agrawal about effective management styles, the failure he experienced teaching for the first time, and a mysterious chrysalis they hit with hammers. Plus an alternative intro theme called "Giggles". Rock on!

What's actually happening in metamorphosis? Why do so many insects do it? Are all butterflies descended from an ancient caterpillar or a ancient butterfly?I sat down with professor Dr. Anurag Agrawal to get some answers.Become a patron of Ecology & Me to keep the questions going: www.Patreon.com/EcologyandMe Follow us on social @ecologyandme Episode recorded, mixed and produced by Kate Douglas Theme song is by Matthew Dean Marsh See acast.com/privacy for privacy and opt-out information.

Andy Dacy, CIO - Global Transport Group and Anurag Agrawal, Investment Specialist, will discuss how the $4 trillion transport market across aircraft, rail, maritime, energy logistics, and heavy equipment sectors presents a resilient, uncorrelated, income-generating alternative to traditional fixed income.

Suffice it to say monarchs have a precarious relationship with milkweed that is literally a matter of life and death. In this episode, we'll talk about monarchs, milkweed, and the remarkable story of their coevolution with Dr. Anurag Agrawal, author of Monarchs and Milkweed. It's an engrossing look at the intricacies of the monarch life cycle and the role a single genus of plant plays in their migration and survival.

The IT industry is undergoing a shift to hybrid and, with that shift, new IT consumption models are gaining ground. In this episode, we explore how customers’ search for choice, simplicity and scalability is leading to adoption of a cloud-like experience across the data center and to as a Service consumption models. This episode’s guests include Phil Davis, Pradeep Kumar, Robert Christiansen, Scott Yow, Jeramiah K. Owyang, Bob O'Donnell, Anurag Agrawal, Sally Eaves, Daniel Newman, Jo Petersen, Ronald Van Loon, Bob Laliberte and Dana Gardner.

While the shift to hybrid cloud presents opportunities for how businesses access and utilize their data, there are still hurdles preventing companies from fully embracing hybrid cloud. In this episode, we’ll explore how standardization and security are necessary to enable data to be more accessible and more normalized across IT environments. This episode’s guests include Robert Christiansen, Scott Yow, Daniel Newman, Jo Petersen, Anurag Agrawal, Dana Gardner and Tim Crawford.

Dr Carolyn Lam:                Welcome to Circulation On The Run, your weekly podcast summary and backstage pass to the journal and it's editors. I'm Dr Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr Greg Hundley:             And I'm Greg Hundley, associate editor from the Pauley Heart Center in Richmond, Virginia at VCU Health.                                                 Well, Carolyn, we've got a great feature article to discuss later in our interview today. We're going to compare surgical versus percutaneous aortic valve replacement, but now with coronary artery revascularization. So, very exciting results from the SURTAVI trial.                                                 So, Carolyn, do you have a couple papers to discuss? Dr Carolyn Lam:                For sure. Actually, it's exactly a couple, and it's a couple of GWAS papers. The first is a GWAS of the cardiac magnetic resonance imaging derived left ventricular phenotypes of the UK bio bank. It comprises almost 17,000 European-UK bio bank participants without prevalent myocardial infarction or heart failure. So this was led by professors Petersen and Monroe from Queen Mary University of London, and colleagues who found that prognostically important left ventricular imaging phenotypes were highly heritable, with a heritability of 22 to 39%. A total of 14 genetic susceptibility low PSI, eight of which were unique, enriched in the cardiac developmental pathways and regulation of contractile mechanisms were discovered, and the polygenic risk scores of left ventricular phenotypes were predictive of heart failure events independently of clinical risk. Dr Greg Hundley:             Well, Carolyn, knowing me and MRI, something I really am interested in. So tell us a little about what are the clinical implications? Dr Carolyn Lam:                Well, the findings not only enhance our understanding of the genetic basis of prognostically important left ventricular phenotypes in the general population, but they also underscore the intricate genetic relationship between these endo phenotypes and the pathogenesis of heart failure. The prioritized genes in the genome whites significant load size should be followed up in the functional studies to aid the development of potential novel therapies in future. The polygenic risk scores of left ventricular phenotypes may have a role in personalized risk stratification. But this, of course, is dependent on further validation of the clinical robustness in future studies.                                                 I want to skip onto my second GWAS paper, and this time dealing with bicuspid aortic valve. So, first a little reminder that bicuspid aortic valve disease is a congenital defect that affects 0.5 to 1.2% of the population, and is associated with comorbidities including ascending aortic dilatation and calcific aortic stenosis. To date, while a few causal genes have been identified, the genetic basis for the vast majority of bicuspid aortic valve cases remains unknown. Today's paper from Dr Lipschultz from Medical University of South Carolina reports novel human genetic based models, which developed bicuspid aortic valve and aortic stenosis with high penetrance. Dr Greg Hundley:             Very interesting. So, how did the authors do this, Carolyn? Dr Carolyn Lam:                Yeah, it is interesting. What they did is they performed a GWAS and replication study using cohorts of more than 2,000 patients with bicuspid aortic valve and more than 2,700 controls, which identified the primary Celia genes as associated with the bicuspid aortic valve phenotype. Specifically the most associated snips were identified in or near genes that are important in regulating Ciliogenesis through the exocyst, which is a shuttling complex that chaperone Celia cargo to the membrane. Genetic dismantling of this exocyst resulted in impaired Ciliogenesis through the XO CIS, disrupted Ciliogenic signaling, and resulted in a spectrum of cardiac defects in zebra fish and aortic valve defects including bicuspid aortic valve, valve stenosis, and Velveeta calcification in murine models as well. So this data really supports that the exocyst is required for normal Ciliogenesis during aortic valve morphogenesis and really implicates the disruption of Ciliogenesis, and its downstream pathways may contribute to bicuspid aortic valve and its associated comorbidities. Dr Greg Hundley:             Wow. Very interesting. Learning more and more about bicuspid valves through our journal. I'm going to shift Carolyn and talk about an article from Dr Marc Sabatine from the TIMI study group at Brigham and Women's hospital. This study performed a systematic review and a trial level meta regression analysis of three classes of lipid lowering therapies that reduce triglycerides to a greater extent than they do LDLC. Fibrates, Niacin, and Marine derived Omega-three fatty acids and key inclusion criteria were a randomized, controlled trial that reported on major vascular events. The study also incorporated data from a previous Meta-regression of 25 Statin trials, and the main outcome measure was the risk ratio for major, vascular events associated with absolute reductions in lipid parameters. Dr Carolyn Lam:                Oh, very interesting. So did the study show that it was beneficial to lower triglycerides or not? Dr Greg Hundley:             Let me tell you a little more about it. The study encompass 374,358 patients that sustained 46,180 major cardiovascular events, and in their multi-variable Meta-regression model, that included terms for both LDLC and triglyceride surrogates for LDL and VLDL. The risk ratio was 0.8 per one millimole per liter reduction in LDLC, and 0.84 per one millimole liter reduction in triglycerides. Therefore, a reduction in non-HDLC, a measure of atherogenic LDL and VLDL particles, is strongly associated with lower risk of major vascular events regardless of the lipid lowering drug class, and triglyceride lowering is associated with a lower risk of cardiovascular events, but to a lesser extent per absolute amount of reduction then with LDLC. Interesting, Carolyn one study reduce it and impacted the study results, and nearly all non-statin trials did not achieve significant non-HDLC lowering to detect a clinical difference in major vascular events. Now how about in regards to Omega- three dose?                                                 Well, each one gram per day of EPA administered was associated with a 7% relative risk reduction in major vascular events, whereas there was no significant reduction in major vascular events with DHA. So the benefits of Marine-derived Omega-three fatty acids, particularly high dose EPA, appear to exceed their lipid lowering effects. Dr Carolyn Lam:                Wow. Interesting. So Greg, take it home for us. What should we do clinically about this information? Dr Greg Hundley:             Carolyn, developing drugs that achieve large reductions in VLDL and triglycerides and are targeting patients with high baseline levels of triglycerides would likely increase the probability of showing a meaningful clinical benefit, and fibrates could be considered in patients needing further non-HDLC lowering, being mindful of side effects, as they should offer clinical benefit proportional to the degree of non-HDLC lowering, and if a disproportionate relationship between lipid lowering and cardiovascular risk reduction is validated in ongoing high dose Omega-three fatty acid trials, it will support the hypothesis that confers a unique benefit of this class of agents beyond simply their lipid lowering.                                                 How about that? Dr Carolyn Lam:                Very nice Greg and I think very balanced and good clinical take home messages. Tell us what else is in the mailbag. Dr Greg Hundley:             We have so many interesting articles in Circulation and let me just run through a quick list of those that are also in this issue. First, Dr Jere Mitchell, from UT Southwestern, reviews the 50th anniversary of the Dallas Bedrest Study that involve five 20-year-olds that underwent several weeks of bedrest, and he discusses how this informs many of our thoughts regarding the benefits of activity today, and one of his major coauthors is Dr Ben Levine. Our own Josh Beckman reviews the ongoing efforts of physicians to understand the role of paclitaxel coated stents for those undergoing peripheral arterial interventions. Dr Berlinde von Kemp, in our case series, identifies that not all cardiomyopathy, after delivery, is simply postpartum cardiomyopathy. In another article, Dr Anurag Agrawal discusses what's on their mind regarding the use of spirometry as a cardiovascular disease risk assessment tool, should it be incorporated into existing cardiovascular disease risk models.                                                 Then, we have a great letter back and forth discussion from Dr Junfeng Wang, Dr Daxin Wang, and our own Naveed Sattar in three separate letters that discussed the relevance of age of onset for type two diabetes relative to cardiovascular risk. Then, finally our own Carolyn Lam reviews the role of biomarkers in heart failure and preserved ejection fraction. Dr Carolyn Lam:                Let's hop on to our feature discussion, shall we? Dr Greg Hundley:             Absolutely. Dr Greg Hundley:             Welcome everyone to the discussion of our featured article today where we're going to review an excellent study comparing TAVR versus SAVR in patients with aortic stenosis, but also now considering simultaneous coronary artery revascularization. Discussing our article today we have Dr Thomas Engstrøm and then our own associate editor, Dharam Kumbhani. Well Thomas, welcome to our podcast featured article discussion. I wonder if you could start us off with a little background regarding your study. What were your hypotheses, and then tell us a little about your study population and your methods. Dr Thomas Engstrøm:     Now, as you know, up to 50% of patients that are treated for aortic stenosis have coronary artery disease, and this may be considered as a bystander disease to develop disease, but definitely also adds to the prognosis for the patients. A priority guideline recommends that if you do SAVR, you'll also have significant coronary artery disease. What we don't know is if the complete percutaneous approach is as good as a surgical approach. Maybe do TAVR plus PCI comply with fiber plus CABG. That's the background for the study.                                                 Now, the population involved in this study is the population from the search TAVR trial, which as you know compared TAVR to SAVR in patients that were clinically at intermediate risk and in patients that had severe aortic stenosis. If patient had additional coronary artery disease with a syntax called Bob 22, they were excluded from the trial. We are talking about intermediate risk patients with low syntax score. Of the patients in the TAVR trial, 20% had additional coronary artery disease and were resterilized. In the paper, we compare TAVR plus PCI versus SAVR plus CABG in those patients with significant coronary artery disease. Dr Greg Hundley:             How did you define the presence or absence of coronary disease? Just real quickly before we get to your results. Dr Thomas Engstrøm:     This was at the discretion of your operator to define where the patients had coronary artery disease or not. In the paper, patients were defined as having significant diseases. More than 70% of stenotic lesions were present in one or more coronary arteries. Dr Greg Hundley:             And so can you tell us, Thomas a little about the results of your study? Dr Thomas Engstrøm:     First of all, the patients that had additional coronary artery disease had a poor prognosis than those that only had valve substitution, which is probably not a surprise. Within those that also had coronary artery disease, TAVR plus PCI appeared to be as good as CABG plus SAVR in terms of the primary endpoint, which was all because mortality or disabling stroke after two years. Then, if you dive more deeply into the endpoint and the number of secondary endpoints were pre-specified, there were no differences regarding any stroke myocardial infraction and in total no differences between what you could call major heart end points. If you look more into detail of the secondary endpoint, there are subtle differences. Patients that were in the SAVR plus CABG had more atrial fibrillation as they also had more acute kidney injury following that treatment. Whereas, in the TAVR plus PCR, more patients had vascular complications and of course had the need for pacemaker implantation. There are differences between the outcome in the two groups, but not in regard of pre-specified primary and more important secondary endpoints. Dr Greg Hundley:             Dharam, I was wondering if you could help us think about what this means for the field in terms of both from aortic valve replacement, and then also the concomitant management of coronary disease in patients that require aortic valve replacement. Dr Dharam Kumbhani:   As Thomas just pointed out, I think this is a very important question. This comes up all the time in patients with severe aortic stenosis, being evaluated for best options, and the guidelines have stayed true to this that if somebody has concomitant coronary artery disease, then the guidelines typically would recommend SAVR as the first option because then they can have CABG at the same time. This study really seeks to address a very important knowledge gap in the field, and as he very well pointed out, this does restrict itself a little in terms of the population, because they couldn't have a high syntax score, actually an intermediate or high syntax score, and they need in the trial...I think the main syntax score was eight or nine. I think that is important, but having said that, more than 50% of the patients had multi-vessel disease, and it was really impressive that nearly 15 or 17% still had three vessel PCI even in this arm.                                                 I think it's important for people to recognize that although this was the lowest syntax score, multivessel PCI was still pursued. I think that's definitely an important takeaway from the strike. It's a really important trial. It's one of the very few pieces of information that we have that is prospectively done under the auspices of a big trial like SURTAVI, and with low risk approval in and what this means for patients going forward I think will be very exciting to see how this few devolves.                                                 Thomas, as this field matures, could you walk us through, in terms of did you do the valve first and then the coronaries, or where the coronaries worked on first and then the valve? That's sort of the first question. Can you walk us through how you make those decisions? Dr Thomas Engstrøm:     It was up to the discretion of the operator whether to do a concomitant procedure, both PCI and TAVR, or to state the procedures in that way that PCI was done first, and this could be done up to seven days before the TAVR. If you compare those two groups, and now numbers become a little bit few, so we can't be conclusive here. It appears that patients that had stage procedures did poorer than those that had concomitant procedures done. Of course, it raises some questions. The prioritization as to do it in one way or the other was that through concomitant procedure, you may introduce too much of stress to the patient. Otherwise, if you do a stage procedure, it's best to do the PCI first, because the actual appearance of the valve may make it more difficult and cumbersome to address the coronary arteries. To sum this up, in the patients that we have, it appeared that a concomitant procedure is safe. Dr Greg Hundley:             Dharam, tell us, what do you think is the next step forward for this field? What do see as the next study moving forward here? Dr Dharam Kumbhani:   I think this study really sets the stage for, I think future trials where perhaps we would have... So I'm doing this in this trial. The stratification was done based on whether or not they need to revascularization. I think going forward, again with LOTUS approval here and proliferation of the number of TAVR procedures that are being offered everywhere, I think it will be helpful. This study would set the stage for future studies, where I think you would prospectively have patients with needing an aortic valve replacement and perhaps even complex revascularization, and how that was kind of actually the randomization, which is the stratification strategy, which again was very helpful. These are really among the first few data that we have of this, but I think this kind of sets the stage for future investigations in this space. And then as I briefly alluded to, I think this may help evolve or this may help in the evolution on the guidelines as well.                                                 Thomas, would you like to add anything to that? Dr Thomas Engstrøm:     Yeah, I completely echo that. Going back to the old syntax trial, it would be very interesting to see if PCI holds through, even in high tunes, syntax scores with newer drug eluting stents, and also of course the question of the diabetics is totally unsolved in this cohort. CABG plus SAVR may turn out to be the best solution, but we still are waiting to see data that can support any of the two strategies in those patient cohorts. Dr Greg Hundley:             We want to thank Thomas Engstrøm and also our own Dharam Kumbhani. We look forward to seeing you next week. Dr Carolyn Lam:                This program is copyright American Heart Association, 2019.  

How does a tiny insect migrate thousands of miles from Canada to Mexico each year? What does the decline of monarch butterflies tell us about the ecological health of our continent? How are scientists using gene editing to understand how insects have evolved to tolerate poisonous plants? Anurag Agrawal is a biologist at Cornell University who studies plant-insect interactions, including monarch butterflies. He is the author of a new book called "Monarchs and Milkweed: A Migrating Butterfly, a Poisonous Plant, and Their Remarkable Story of Coevolution.” On this episode, Art and Marty talk with Anurag about the incredible migration of the monarch butterfly, the recent decline in population and a fascinating study where scientists edited the genomes of fruit flies to make them resistant to a poisonous plant that monarchs eat. --- Send in a voice message: https://anchor.fm/bigbiology/message

In 2018, scientists reported dramatic losses in populations of one of North America’s most charismatic insects, the Monarch butterfly, with an estimated 14.8 percent decline of Eastern Monarchs and a precipitous 86% percent 1-year decline in Western Monarchs. While Monarchs are known for seasonal fluctuations in their numbers, this week we speak with Monarch researcher Dr. Anurag Agrawal of Cornell University to learn more. Cultivating Place now has a donate button! We thank you so much for listening over the years and we hope you'll support Cultivating Place. We can't thank you enough for making it possible for this young program to grow even more of these types of conversations. For photos visit www.cultivatingplace.com. The show is available as a podcast on SoundCloud, iTunes, Google Play and Stitcher.

Anurag Agrawal, CEO and Analyst at Techaisle: INSIGHTS MATTER: Techaisle’s Survey Results for Mid-Market Firms

Anurag Agrawal author of Monarchs and Milkweed speaks to us on the topics that are most interesting to us.  Book title - Monarchs and Milkweed: A Migrating Butterfly, a Poisonous Plant, and Their Remarkable Story of Coevolution Grow Milkweed Plants podcast - Season 3 Episode 3 Read the recent blog posts by todays guest. Click on the titles which are links to monarchs and milkweed in Oxaca Mexico and the surrounding area.  Monarchs & Milkweed in Mexico – Pt 1 Posted on January 16, 2018 by Anurag Agrawal Monarchs & Milkweed in Mexico - Pt II Posted on January 28, 2018 by Anurag Agrawal Listen to the sounds of the monarch butterflies by locating Cerro Pelon on the SoundMap provided by Locus Sonus. Be sure to tune in during the daylight hours because that is when the monarchs are active but more important is that the microphone is powered by solar energy and the location only appears on the map when the sun is shining on the monarch butterflies. ​http://locusonus.org/soundmap/051/ View the book which is available from Amazon (press and hold link below) Monarchs and Milkweed: A Migrating Butterfly, a Poisonous Plant, and Their Remarkable Story of Coevolution   Host: Brad Grimm Intro Music: sunny - Bensound.com Outro Music: acusticbreeze - Bensound.com

Prof. Anurag Agrawal, Business Policy area of IIM Ahmedabad in conversation with Preetham Gandhi Sunkavalli PGP Batch of 2016-18 at IIMA discusses on New Collar Jobs: Business, Legal and Political Implications

In order to get ahead of your competition this year, it’s important to know what trends are likely to play out in the IT channel. So what can you expect in 2015? On this episode of MSPradio, we chat with Anurag Agrawal, CEO of TechAisle, who discusses 5 of his 15 predictions for the SMB Channel in 2015 and how he thinks it will impact MSPs. Tune in now and hear about what you can look forward to in 2015.

The SMB industry is a constantly changing market, which provides a constant opportunity for MSPs. However, it’s important to understand these changes so that you can understand the opportunities at hand. And what better way to understand these opportunities than data? On this episode of MSPradio, we’re joined by an SMB expert, Anurag Agrawal, CEO of TechAisle. He talks about the state of small business, where SMB IT priorities are and how MSPs can take advantage. And of course, he backs it all up with cold-hard data! Tune in to this week’s episode of MSPradio!

In this month's Cell Podcast, we learn how plant defenses have shaped the fussy dining habits of insects, with Anurag Agrawal (0:00) (Trends in Plant Science Special Issue), why after twenty years, John O’Shea is still excited about cytokine signaling, (8:34) (Immunity Special Feature on the JAK-STAT pathway), and why being the right size is a matter of life or death for free-falling rodents, with Andrew Spence (15:15) (Current Biology Special Issue on Size Control). Plus, sample a selection of the hottest new papers from Cell Press (20:46).